Hand holding the newspaper resting on a table with a cup of coffee


Taxonomy Icon
Drug Researchers Need to Learn to “Fail Fast”
  • March 10, 2021
  • Source: Techonomy
In this Techonomy exclusive from Dr. Nader Sanai, director of the Ivy Brain Tumor Center, he discusses the "fail fast" adage associated with Silicon Valley and the implications this method could have on the healthcare industry specifically, in clinical trials.
Taxonomy Icon
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
  • March 10, 2021
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM). This is the first Phase 0 clinical trial open to newly diagnosed glioblastoma patients.
Taxonomy Icon
Research and Medical Technology Advances Offer Hope for Patients with Aggressive Brain Cancer
  • March 4, 2021
  • Source: BioSpace
BioSpace highlights the Ivy Brain Tumor Center's new drug-device combination treatment for glioblastoma. This article depicts the collaborative effort between the Ivy Center and SonALAsense and the promising GBM therapy on the horizon.
Taxonomy Icon
Promising treatment for deadly Glioblastoma being tested on humans at Ivy Brain Tumor Center
  • January 15, 2021
  • Source: Chamber Business News
A promising non-invasive treatment to effectively and safely destroy deadly brain tumors is being tested on human patients for the first time ever at the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix.
Taxonomy Icon
First-in-class Noninvasive Therapy for Glioblastoma Enters Phase 0 Trial at Ivy Brain Tumor Center
  • January 4, 2021
  • Source: Onco'Zine
Earlier this year, the Ivy Brain Tumor Center received FDA approval for a Phase 0 clinical trial to study a first-in-human drug-device combination that uses MRI-guided focused ultrasound in combination with aminolevulinic acid to selectively target and kill tumor cells. Peter Hofland of Onco'Zine covers the story in this article and what it could mean for the brain tumor community.
Taxonomy Icon
SonALAsense Pioneers Sonodynamic Therapy, a First-in-Class Noninvasive Therapy for Lethal Brain Cancers; Enters Into a Collaboration and License Agreement With Insightec and a Collaboration Agreement with Ivy Brain Tumor Center to Conduct the First-in-Man Clinical Trial for Recurrent Glioblastoma
  • December 17, 2020
The Ivy Brain Tumor Center is excited to collaborate with SonALAsense to conduct this first-in-human clinical trial that will rapidly assess a noninvasive drug-device combination therapy in patients with glioblastoma. This marks a major step forward for brain cancer patients as this novel approach has the potential to change the lives of hundreds of thousands of people impacted by this disease.
Taxonomy Icon
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
  • December 16, 2020
The Ivy Brain Tumor Center is conducting the first-ever Phase 0 clinical trial for newly diagnosed glioblastoma patients. This study will evaluate BeiGene’s pamiparib in combination with fractionated radiotherapy and will also be available to patients with recurrent glioblastoma.
Taxonomy Icon
Re-Thinking Brain Tumor Drug Development
  • November 9, 2020
In the eleventh annual edition of the International Brain Tumour Alliance (IBTA) magazine, Dr. Nader Sanai explains how the Ivy Brain Tumor Center's unique Phase 0 clinical trials program is providing tailored care for individuals struggling with brain cancer.
Taxonomy Icon
Meet Jacki Garcia: Nurse Navigator, Neurosurgical Oncology
  • October 30, 2020
  • Source: Barrow Neurological Institute
Navigating a brain tumor diagnosis can be overwhelming. That's where Jacki Garcia comes in. Jacki is a nurse navigator for Barrow patients with brain tumors, including those who undergo Phase 0 clinical trials at the Ivy Brain Tumor Center.
Taxonomy Icon
Ivy Center Researcher Awarded Prestigious NIH Grant
  • October 9, 2020
Zaman Mirzadeh, MD, PhD, an assistant professor and neurosurgeon-scientist at the Ivy Brain Tumor Center and Barrow Neurological Institute, has been named a recipient of the National Institutes of Health (NIH) Director’s New Innovator Award.